US FDA warns of unapproved, phony Botox
This article was originally published in Scrip
Executive Summary
US regulators said about 350 medical practices may have received phony versions of Allergan's Botox (onabotulinumtoxinA) and other drugs, which were shipped by a foreign supplier, with the FDA warning doctors that those unapproved products may be contaminated, improperly stored and transported, ineffective or unsafe.